123I-meta-iodobenzylguanidine (MIBG) cardiac scintigraphy in α-synucleinopathies

Satoshi Orimo, Makiko Yogo, Tomohiko Nakamura, Masahiko Suzuki, Hirohisa Watanabe

Research output: Contribution to journalReview articlepeer-review

64 Citations (Scopus)


Cardiac meta-iodobenzylguanidine (MIBG) uptake on 123I-MIBG cardiac scintigraphy is reduced in patients with Lewy body disease such as Parkinson's disease (PD), dementia with Lewy bodies (DLB), and pure autonomic failure, and has been reported to be useful for differentiating PD from other parkinsonian syndromes, as well as DLB from Alzheimer disease (AD). Postmortem studies have shown that the number of tyrosine hydroxylase (TH)-immunoreactive nerve fibers of the heart was decreased in pathologically-confirmed Lewy body disease, supporting the findings of reduced cardiac MIBG uptake in Lewy body diseases. Now, reduced cardiac MIBG uptake can be a potential biomarker for the presence of Lewy bodies in the nervous system. 123I-MIBG cardiac scintigraphy can allow us to determine the presence of Lewy bodies.

Original languageEnglish
Pages (from-to)122-133
Number of pages12
JournalAgeing Research Reviews
Publication statusPublished - 01-09-2016
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Biochemistry
  • Ageing
  • Molecular Biology
  • Neurology


Dive into the research topics of '123I-meta-iodobenzylguanidine (MIBG) cardiac scintigraphy in α-synucleinopathies'. Together they form a unique fingerprint.

Cite this